共 50 条
- [21] Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumorsINTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 563 - 572Falchook, Gerald S.Venkatakrishnan, KarthikSarantopoulos, JohnKurzrock, RazelleMita, Alain C.Fu, SiqingMita, Monica M.Zhou, XiaofeiJung, Jung AhUllmann, Claudio DanskyMilch, CatherineRosen, Lee S.
- [22] Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cellsCANCER CELL INTERNATIONAL, 2020, 20 (01)Yang, YanDing, LiliZhou, QiFen, LiCao, YuhuaSun, JunjieZhou, XuefengLiu, Aiguo
- [23] Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cellsCancer Cell International, 20Yan YangLili DingQi ZhouLi FenYuhua CaoJunjie SunXuefeng ZhouAiguo Liu
- [24] FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORSANNALS OF ONCOLOGY, 2012, 23 : 168 - 168Falchook, G. S.Zhou, X.Rosen, L. S.Venkatakrishnan, K.Kurzrock, R.Mahalingam, D.Goldman, J.Jung, J.Milch, C.Sarantopoulos, J.
- [25] Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaBLOOD, 2010, 115 (25) : 5202 - 5213Goerguen, GuellueCalabrese, ElisabettaHideshima, TeruEcsedy, JeffreyPerrone, GiuliaMani, MalaIkeda, HiroshiBianchi, GiadaHu, YiguoCirstea, DianaSanto, LoredanaTai, Yu-TzuNahar, SabikunZheng, MeiBandi, MadhaviCarrasco, Ruben D.Raje, NoopurMunshi, NikhilRichardson, PaulAnderson, Kenneth C.
- [26] Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignanciesEUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S77Zhou, X.Nemunaitis, J.Pant, S.Bauer, T. M.Patel, M.Sarantopoulos, J.Lockhart, A. C.Goodman, D.Zhang, B.Ullmann, C. DanskyMould, D. R.Venkatakrishnan, K.
- [27] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Dees, E. C.Infante, J. R.Burris, H. A.Astsaturov, I. A.Stinchcombe, T.Liu, H.Galvin, K.Venkatakrishnan, K.Fingert, H. J.Cohen, R. B.
- [28] The Aurora A Kinase Inhibitor MLN8237 Significantly Enhances the Antitumor Activity of Oncolytic Measles Virus Derivatives in the Treatment of GlioblastomaMOLECULAR THERAPY, 2012, 20 : S166 - S166Allen, CoryIankov, IankoOpyrchal, MateuszKeith, Lucas A. G.Schroeder, Mark A.Sarkaria, Jann N.Ecsedy, JeffreyGalanis, Evanthia
- [29] The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibJOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2011, 15 (10) : 2057 - 2070Kelly, Kevin R.Ecsedy, JeffreyMedina, ErnestMahalingam, DevalingamPadmanabhan, SwaminathanNawrocki, Steffan T.Giles, Francis J.Carew, Jennifer S.
- [30] A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Beltran, HimishaRubin, Mark A.Mosquera, Juan MiguelChristos, Paul J.Calukovic, OliveraKarpenko, IrenePinski, Jacek K.Danila, Daniel CostinNanus, David M.Tagawa, Scott T.